Lyra Therapeutics, Inc.

NasdaqGM:LYRA Rapporto sulle azioni

Cap. di mercato: US$16.9m

Lyra Therapeutics Performance dei guadagni passati

Il passato criteri di controllo 0/6

Lyra Therapeutics's earnings have been declining at an average annual rate of -34.1%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually. Revenues have been growing at an average rate of 51.7% per year.

Informazioni chiave

-34.1%

Tasso di crescita degli utili

92.5%

Tasso di crescita dell'EPS

Pharmaceuticals Crescita del settore6.0%
Tasso di crescita dei ricavi51.7%
Rendimento del capitale proprio-327.3%
Margine netto-5,570.9%
Ultimo aggiornamento sui guadagni30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

Jan 25
Will Lyra Therapeutics (NASDAQ:LYRA) Spend Its Cash Wisely?

We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Sep 10
We Think Lyra Therapeutics (NASDAQ:LYRA) Needs To Drive Business Growth Carefully

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 12
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Lyra Therapeutics appoints Nieman as Chief Medical Officer

Jul 05

Lyra Therapeutics: Progress In The Clinic

May 18

A First Look At Lyra Therapeutics

Apr 21

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Mar 30
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Deliver On Growth Plans?

Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

Dec 14
Is Lyra Therapeutics (NASDAQ:LYRA) In A Good Position To Invest In Growth?

We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

Aug 28
We Think Lyra Therapeutics (NASDAQ:LYRA) Can Afford To Drive Business Growth

We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

May 04
We're Not Very Worried About Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Rate

How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Mar 05
How Many Lyra Therapeutics, Inc. (NASDAQ:LYRA) Shares Do Institutions Own?

Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Jan 11
Companies Like Lyra Therapeutics (NASDAQ:LYRA) Are In A Position To Invest In Growth

Lyra Therapeutics down 19% underwhelming data from lead program

Dec 07

Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

Nov 24

Ripartizione dei ricavi e delle spese

Come Lyra Therapeutics guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.


Storia dei guadagni e delle entrate

NasdaqGM:LYRA Ricavi, spese e utili (USD Millions )
DataRicaviGuadagniSpese G+ASpese di R&S
30 Jun 242-101200
31 Mar 242-69200
31 Dec 232-63190
30 Sep 231-62190
30 Jun 231-61170
31 Mar 231-60180
31 Dec 221-55180
30 Sep 222-55180
30 Jun 221-51170
31 Mar 221-48160
31 Dec 210-44140
30 Sep 210-37160
30 Jun 210-3214-5
31 Mar 210-2611-3
31 Dec 200-22100
30 Sep 200-2083
30 Jun 200-18611
31 Mar 200-17512
31 Dec 190-17412
31 Dec 181-645

Guadagni di qualità: LYRA is currently unprofitable.

Margine di profitto in crescita: LYRA is currently unprofitable.


Flusso di cassa libero e analisi degli utili


Analisi della crescita degli utili nel passato

Andamento degli utili: LYRA is unprofitable, and losses have increased over the past 5 years at a rate of 34.1% per year.

Accelerare la crescita: Unable to compare LYRA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Guadagni vs Settore: LYRA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).


Rendimento del capitale proprio

ROE elevato: LYRA has a negative Return on Equity (-327.31%), as it is currently unprofitable.


Rendimento delle attività


Rendimento del capitale investito


Scoprire le aziende con forti performance passate